H1 N1
•
6 likes•6,789 views
The document summarizes information about the H1N1 influenza virus (swine flu), including its origins, signs and symptoms, transmission, diagnosis, treatment, and preventive measures. It notes that the first cases of human infection with the novel H1N1 virus were detected in 2009. Symptoms are similar to seasonal flu and it spreads through respiratory droplets. Diagnosis involves laboratory tests. Treatment involves antiviral drugs like oseltamivir and zanamivir. Preventive measures include hand washing, cough etiquette, and staying home when sick.
![H1N1 Influenza ,[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
More Related Content
What's hot
What's hot (20)
Similar to H1 N1
Similar to H1 N1 (20)
More from CONSULTANT IN OBGYN, ODISHA ,INDIA
More from CONSULTANT IN OBGYN, ODISHA ,INDIA (20)
Recently uploaded
Recently uploaded (20)
H1 N1
- 1. Swine Flu(H1N1) Dr Sujnanendra Mishra MD (O&G )
- 7. H1N1 A GLOBAL ISSUE
- 13. Swine Influenza A(H1N1) Treatment Source: CDC Dosing recommendations for antiviral treatment of children younger than 1 year using oseltamivir. Recommended treatment dose for 5 days. <3 months: 12 mg twice daily; 3-5 months: 20 mg twice daily; 6-11 months: 25 mg twice daily Dosing recommendations for antiviral chemoprophylaxis of children younger than 1 year using oseltamivir. Recommended prophylaxis dose for 10 days. <3 months: Not recommended unless situation judged critical due to limited data on use in this age group; 3-5 months: 20 mg once daily; 6-11 months: 25 mg once daily Oseltamivir (Tamiflu) Zanamivir (Relenza) Treatment Prophylaxis Treatment Prophylaxis Adults 75 mg capsule twice per day for 5 days 75 mg capsule once per day Two 5 mg inhalations (10 mg total) twice per day Two 5 mg inhalations (10 mg total) once per day Children 15 kg or less: 60 mg per day divided into 2 doses 30 mg once per day Two 5 mg inhalations (10 mg total) twice per day (age, 7 years or older) Two 5 mg inhalations (10 mg total) once per day (age, 5 years or older) 15–23 kg: 90 mg per day divided into 2 doses 45 mg once per day 24–40 kg: 120 mg per day divided into 2 doses 60 mg once per day >40 kg: 150 mg per day divided into 2 doses 75 mg once per day
- 19. NO HANDSHAKE PLEASE !! SAY NAMASTE !! Wash your hands frequently and thoroughly. wear a face mask, if available and tolerable,
- 20. NAMASKAR
Editor's Notes
- For the most current number of human cases visit the CDC H1N1flu website: http://www.cdc.gov/h1n1flu/investigation.htm . CDC, along with state and local health agencies, are working together to investigate this situation. Numbers are updated every at 11:00 AM EDT.
- Influenza primarily infects the respiratory tract (nose, throat, and lungs). The disease can cause severe illness and lead to life-threatening complications, such as pneumonia, in many people.
- It is thought that the main way influenza viruses are spread from person to person is through transmission of respiratory droplets during coughing and sneezing. Close contact (about 3 feet or less) usually is necessary for this type of spread. Influenza viruses also can spread by touching respiratory droplets on yourself, others, or an object, then touching mucus membranes, such as the mouth, nose, or eyes, without washing contaminated hands.
- Pregnant Women Oseltamivir and zanamivir are &quot;Pregnancy Category C&quot; medications, indicating that no clinical studies have been conducted to assess the safety of these medications for pregnant women. Because of the unknown effects of influenza antiviral drugs on pregnant women and their fetuses, oseltamivir or zanamivir should be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus; the manufacturers' package inserts should be consulted. However, no adverse effects have been reported among women who received oseltamivir or zanamivir during pregnancy or among infants born to women who have received oseltamivir or zanamivir. Pregnancy should not be considered a contraindication to oseltamivir or zanamivir use. Because of its systemic activity, oseltamivir is preferred for treatment of pregnant women. The drug of choice for prophylaxis is less clear. Zanamivir may be preferable because of its limited systemic absorption; however, respiratory complications that may be associated with zanamivir because of its inhaled route of administration need to be considered, especially in women at risk for respiratory problems. Adverse Events: http://www.cdc.gov/flu/professionals/antivirals/side-effects.htm
- More information can be found at http://www.cdc.gov/ncidod/dhqp/gl_environinfection.html